Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous daratumumab in moderate to severe ME/CFS (pilot)
2022-000281-18Phase 2Active
- Sponsor
- Haukeland University Hospital
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in myalgic encephalomyelitis (ME), sponsored by Haukeland University Hospital. Primary endpoint: Safety and tolerability. Started Feb 2022; status: active.
02
Drugs
daratumumab
03
Conditions
myalgic encephalomyelitis (ME)
Beyond the preview
Go deeper on 2022-000281-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000281-18.